PLGA-mediated Targeted Drug Delivery System for Atherosclerotic Cardiovascular Disease

Votes: 29
Views: 4326

Atherosclerosis is a long-term inflammatory condition that builds up inflammatory cells and fat in artery walls, which can cause serious cardiovascular problems. Because current therapies focus exclusively on certain components of the condition, such as inflammation or cholesterol, they frequently fall short of addressing the disease's complex nature. Our novel approach addresses cholesterol build up, oxidative stress, and inflammation all at once with a multi-layered medication delivery device. Within a core-shell structure, the system incorporates natural chemicals from Prosopis juliflora and Calotropis gigantea. These would act in such a way that deactivates LDL molecules, breaks down inflammatory cells, and stabilizes plaques. A multi-layered drug delivery system designed specifically target atherosclerotic plaques and mitigate disease progression.

Utilizing biodegradable polymers (PLGA) as the outer layer (Core shell), our system achieves targeted delivery to coronary arteries via receptor-mediated interactions. The layers incorporated with Calotropis gigantea milkweeds , leveraging its enzymatic, adhesive, and anti-inflammatory properties through proteolytic enzymes, reducing inflammation within plaques. Meanwhile, the inner layer gum sap from Prosopis juliflora, which effectively engulfs and inactivates low-density lipoprotein (LDL) molecules, thus mitigating cholesterol accumulation and oxidative stress. By lowering oxidative stress and preventing cholesterol build up, and targeting many pathogenic processes of atherosclerosis and avoiding the negative effects associated with synthetic medicines, this holistic strategy offers improved patient outcomes.


Learn how to vote for your favorites.


  • Name:
    Eswara G R
  • Type of entry:
    Team members:
  • Patent status: